Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Director, Thought Leadership
12+ years of experience
Daniel has a decade of experience as an analyst in the biopharma industry, spanning roles in drug discovery, market analysis, competitive intelligence, and strategic consulting. He covers topics such as COVID-19, immuno-oncology, tumour-agnostic drug development, artificial intelligence, and mergers and acquisitions (M&A), and regularly participates in webinars, conferences, and other speaking arrangements.
Daniel is featured across leading publications such as Nature Reviews Drug Discovery, Fortune, Scientific American, Scrip, In Vivo and Vice.
Prior to joining Informa, Daniel worked as a medicinal chemist at the U.K. biotech company Summit Therapeutics and graduated with First Class Honours in Natural Sciences from the University of Bath.
Datamonitor Healthcare
By Daniel Chancellor 23 Jun 2021
The Butterfly Effect is an elegant analogy to describe the seemingly unpredictable and far-reaching implications of a relatively small and inconsequential event.
Topic Alzheimer's Disease
Trialtrove
By Daniel Chancellor 04 Mar 2021
Disruption to clinical trials was a well-documented side effect of the COVID-19 pandemic, with trial sponsors and clinical sites dramatically scaling back activities in line with increased hospital burden, lockdown measures, and reduced patient mobility.
Topic Coronavirus Clinical Trials Clinical Trials Blog BioPharmaceutical
In Vivo
By Daniel Chancellor 03 Mar 2021
Biopharma’s accomplishments in tackling the global COVID-19 pandemic, unlike advances within oncology such as cell therapies and checkpoint inhibitors, or functional cures for HIV and hepatitis C, have captured the public’s imagination. Consequently, industry perception scores have ticked upwards sharply, albeit from a low base.
Biomedtracker
By Daniel Chancellor 27 Nov 2020
Using M&A activity as a barometer for the overall health of the biopharma industry, we explore biopharma’s biggest deals of the past decade and examine what they may presage for the year to come. Dive into key insights on trends, M&A drivers, companies to watch, and more.
Topic M A
In Vivo
By Daniel Chancellor 26 Nov 2020
“Pipeline-in-a-pill” has increasingly entered the biopharma executive’s vernacular, denoting an attractive asset that has considerable sales potential owing to the number of discrete patient populations it can target. While the phrase or concept may be in vogue, in reality it is one of the many guises or iterations of lifecycle management.
Topic BioPharmaceutical Drug Pricing Drug Review Drug Development Landscape
Scrip
By Daniel Chancellor 27 Jan 2020
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.
Datamonitor Healthcare
By Daniel Chancellor 11 Jun 2019
In April, immuno-oncology (IO) celebrated its ninth birthday, following the approval of Provenge, the first drug that harnesses the body’s immune system to fight cancer, in April 2010. Since this landmark event, it has been a tremendous decade for the field, with IO becoming part of the standard-of-care in a range of treatment settings and the Nobel Prize being awarded for the discovery of immune checkpoint inhibition. It is the checkpoint inhibitor drug classes that are leading the IO revolution and will act as a foundation for the next decade of oncology research. This article reviews the childhood years of IO and predicts what the future may hold as it reaches double digits and matures through adolescence.
Topic Cancer
Datamonitor Healthcare
By Daniel Chancellor 01 Mar 2017
New clinical data and a deepening treatment algorithm will drive market growth
Topic Research Wire
Datamonitor Healthcare
By Daniel Chancellor 22 Jan 2016
Alkermes has announced the failure of two of its pivotal trials for its novel opioid-targeting antidepressant ALKS 5461
Datamonitor Healthcare
By Daniel Chancellor 22 Jan 2016
Alkermes has announced the failure of two of its pivotal trials for its novel opioid-targeting antidepressant ALKS 5461 (buprenorphine/samidorphan), yet is emboldened by an efficacy signal
Topic Alkermes
Datamonitor Healthcare
By Daniel Chancellor 02 Aug 2015
Entering a established market as a new player can be daunting. It's difficult to know exactly where you should be targeting your trial, and also who you should be targeting your treatment at.
Topic Parkinson's Disease
Datamonitor Healthcare
By Daniel Chancellor 23 Jul 2015
Biogen and Eli Lilly both presented much-anticipated data at the 2015 Alzheimer’s Association International Conference (AAIC) in Washington DC for their respective anti-beta amyloid
Topic Alzheimer's Disease
Datamonitor Healthcare
By Daniel Chancellor 02 Jun 2015
With ASCO over for another year we’ve put together an overview of key highlights from this year’s conference. Our NEW white paper allows you to read through the results and implications of these key abstracts, chosen by our expert analysts, allowing you and your business to evolve with the oncology market.
Datamonitor Healthcare
By Daniel Chancellor 14 Nov 2014
Download your free infographic using the adjacent form. Get to grips with early-phase opportunities in our depression pipeline with our latest infographic.
Datamonitor Healthcare
By Daniel Chancellor 17 Sep 2014
The US Food and Drug Administration (FDA) has approved Orexigen’s Contrave (naltrexone + bupropion) for the treatment of obesity, while panelists on an FDA advisory committee voted in favor
Topic Approvals
In Vivo
13 Jun 2022
In Vivo
07 Mar 2022
In Vivo
17 Nov 2021
In Vivo
12 Jul 2021
Scrip
26 Jan 2016
Scrip
13 Oct 2015
